Pradaxa Legal News Articles & Interviews

Philadelphia, PA: A jury has found against units of Johnson & Johnson (J&J) and Bayer AG in the fourth bellwether Xarelto (Rivaroxaban) case being heard as part of a Xarelto mass tort. The award, nearly $28 million, is the first favoring a plaintiff, in this case Lynn Hartman, who alleged she suffered a serious gastrointestinal bleed while using the blood thinning medication. The jury found that the pharmaceutical companies failed to provide adequate warnings regarding the risks for bleeding associated with Xarelto.

Hartford, CT: Even though Pradaxa and a competitor were brought to market as an easier-to-manage alternative to warfarin, previously the gold standard for blood thinning, no one disputes the fact that all anti-coagulants carry a risk for bleeding events. However, it is alleged in Pradaxa lawsuits that some blood thinners carry a greater risk for bleeding events than others.

Toronto, ON: In tandem with oft-cited Pradaxa bleeding associated with the frequently-prescribed blood thinner, a new concern has emerged from a Canadian study suggesting that Pradaxa use with certain statins can heighten the risk for bleeding for patients suffering from atrial fibrillation.

Boston, MA: Having already paid out $650 million in settlement dollars over lawsuits in 2014, attorneys for the makers of dabigatran Pradaxa are busy attempting to escape a wrongful death lawsuit scheduled for December. It would be the first federal lawsuit over Pradaxa, set to commence next month.

Hartford, CT: Boehringer Ingelheim Pharmaceuticals (Boehringer) was the first to lob a new anti-coagulant into a marketplace crying for an easier way to manage or reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. However dabigatran (Pradaxa), according to various Pradaxa lawsuits, did not turn out to be the savior it was touted to become, with plaintiffs alleging that Boehringer failed to adequately disclose the lack of a reversing agent.

Hartford, CT: As we move into September and an end to the summer season with a return to classes, it’s instructive to revisit the onset of summer two years ago and the $650 million Pradaxa side effects settlement offered by Pradaxa manufacturer Boehringer Ingelheim over its troubled new-age blood thinner.

Washington, DC If you need an anticoagulant and are given a choice of Pradaxa or warfarin, chances are you would not opt for Pradaxa, unless you wanted to bleed to death.

Washington, DC One of the biggest concerns about Pradaxa side effects, and the side effects of other new generation anticoagulants, is that there is no approved antidote for certain adverse events. Pradaxa lawsuits have alleged that the maker of the drug did not warn patients about the lack of an antidote, putting them at risk of Pradaxa bleeding events. Now comes word that a Pradaxa antidote could be along in the near future.

Washington, DC Although it is a relatively new drug on the market, Xarelto side effects reports have reportedly surpassed those of rival drug Pradaxa, according to one organization. Both drugs are anticoagulants and both have been linked to an increased risk of bleeding complications. But while some Pradaxa lawsuits have been settled, Xarelto litigation is just now gearing up.

Louisville, KY Attorney David Koon sees more litigation ahead for anticoagulant Xarelto. Some is already in progress, but given the drug’s similarity to Praxada, another oral blood thinner with similar properties, Koon’s firm, Hughes & Coleman, is already preparing for failure to warn and product liability cases on behalf of people injured by Xarelto.